Onco-hematology
Cohort Study | Prognostic value of FLT3-internal tandem duplication residual disease in AML.
3 Nov, 2022 | 13:36h | UTC
Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
31 Oct, 2022 | 13:36h | UTC
Commentary on Twitter
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab https://t.co/hw7Tp9yjdu pic.twitter.com/CqMu2cMqRc
— Blood Journal (@BloodJournal) August 31, 2022
Case Report | Acquired Hemophilia A secondary to an immune checkpoint inhibitor.
31 Oct, 2022 | 13:34h | UTCCommentary: Report Details Rare Case of Acquired Hemophilia A Secondary to Immune Checkpoint Inhibition
Recommendations for laboratory testing of patients with acute myeloid leukemia.
25 Oct, 2022 | 13:21h | UTC
Systematic Review | Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
21 Oct, 2022 | 12:47h | UTC
Guideline | Diagnosis and management of febrile neutropenia in patients with cancer.
18 Oct, 2022 | 12:52h | UTCRelated:
Guidance | Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology.
13 Oct, 2022 | 13:46h | UTC
Cohort Study | Cardiovascular morbidity in monoclonal gammopathy of undetermined significance.
13 Oct, 2022 | 13:34h | UTC
Phase 1 study | GPRC5D-Targeted CAR T Cells for patients with heavily pretreated Multiple Myeloma.
29 Sep, 2022 | 13:25h | UTCGPRC5D-Targeted CAR T Cells for Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations.
23 Sep, 2022 | 13:07h | UTC
Commentary on Twitter
Chimeric antigen receptor T cells have revolutionised the treatment of hematological malignancies.
What practical aspects of a patient’s journey through this treatment should clinicians know about and what are current best practices to manage toxicities?https://t.co/idlA2Lv9uR
— The BMJ (@bmj_latest) September 4, 2022
NCCN Guideline | Myeloproliferative neoplasms.
15 Sep, 2022 | 13:05h | UTC
Retrospective cohort study | Tisagenlecleucel (an anti-CD19 CAR T-cell therapy) for relapsed or refractory B-cell acute lymphoblastic leukemia in infants and children younger than 3 years of age at screening.
13 Sep, 2022 | 12:59h | UTCCommentaries:
CD19 CAR T cells for infants and young children – The Lancet Haematology (free registration required)
CAR-T Therapy Effective in Youngest Kids With ALL — Analysis shows safety and outcomes equivalent to those reported in older children – MedPage Today (free registration required)
Commentary on Twitter
NEW research—tisagenlecleucel has antitumour activity and acceptable safety in young children and infants (aged younger than 3 years at screening) with B-cell ALL: results of an international, retrospective study #leusm #pedonc #tcellrx https://t.co/kdh3dW5PRU pic.twitter.com/FgQZKQWtXV
— The Lancet Haematology (@TheLancetHaem) September 8, 2022
RCT | Busulfan plus Cyclophosphamide is noninferior to total body irradiation plus Cyclophosphamide for adults Acute B Lymphoblastic Leukemia.
11 Sep, 2022 | 22:24h | UTC
Large study unravels the risk factors for heart failure among childhood cancer survivors.
11 Sep, 2022 | 22:22h | UTC
RCT | Lenalidomide-dexamethasone vs. observation in high-risk smoldering myeloma after 12 years of median follow-up time.
8 Sep, 2022 | 14:34h | UTCLenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study – European Journal of Cancer (link to abstract – $ for full-text)
Review | Diagnosis and treatment of myelodysplastic syndromes.
7 Sep, 2022 | 12:33h | UTCDiagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Myelodysplastic Syndromes – JAMA
Cohort Study | Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria.
7 Sep, 2022 | 12:29h | UTCClinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Super excited to share our multicenter study on clonal evolution in 1008 patients with AA/PNH followed for a median f-up of 9 yrs now out in @JCO_ASCO https://t.co/j9U2ZjYX0o
— Carmelo Gurnari (@CarmeloGurnari) September 2, 2022
Long-term results of a RCT | Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in chronic lymphocytic leukemia.
31 Aug, 2022 | 11:32h | UTCCommentary: Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status – Cancer Network
Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.
26 Aug, 2022 | 13:05h | UTCSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Long-term results of a RCT | Lenalidomide plus Rituximab vs. Rituximab-chemotherapy followed by Rituximab maintenance in untreated advanced Follicular Lymphoma.
26 Aug, 2022 | 13:03h | UTCCommentaries:
Commentary on Twitter
6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
M-A | Interventions to reduce infections in patients with hematological malignancies.
15 Aug, 2022 | 11:51h | UTCCommentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC
Long-term results of a phase 2 RCT | Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma.
15 Aug, 2022 | 11:46h | UTCOriginal Study: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
RCT | Low-dose Decitabine vs. low-dose Azacitidine in lower-risk myelodysplastic syndromes.
11 Aug, 2022 | 12:04h | UTCLow-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence
Commentary on Twitter
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. https://t.co/OSpNLzfiKW#MDS #LeuSM #CMML pic.twitter.com/BN1XAhfUBo
— NEJM Evidence (@NEJMEvidence) August 9, 2022
Single-arm phase 2 study | Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma.
9 Aug, 2022 | 12:22h | UTCLong-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
? Combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with relapsed/refractory #MultipleMyeloma ➡️ https://t.co/TkPRcTKSxg #JCO #MMSM pic.twitter.com/0OZAJtTXF1
— Journal of Clinical Oncology (@JCO_ASCO) April 15, 2022
Guideline | Management of antithrombotic treatments in thrombocytopenic patients with cancer.
5 Aug, 2022 | 14:37h | UTC